Last updated: April 28, 2026
Litigation Summary and Patent-Strategy Analysis: Sanofi v. Unimark Remedies Ltd. (1:14-cv-00876)
What is the case and what did Sanofi sue on?
Sanofi v. Unimark Remedies Ltd., case number 1:14-cv-00876, is a U.S. federal patent litigation brought by Sanofi against Unimark Remedies Ltd. The docket number identifies the matter as a patent dispute in the District Court system, with the litigation posture consistent with Abbreviated New Drug Application (ANDA) / Hatch-Waxman framework.
The case title appears on the federal docket as:
- Sanofi v. Unimark Remedies Ltd.
- 1:14-cv-00876 (U.S. District Court)
Status information and specific asserted patent numbers, claim constructions, and case outcomes are not present in the information provided here, so no further case-specific merits analysis can be produced without fabricating details.
What relief did Sanofi seek?
In ANDA-linked patent suits, plaintiffs typically seek:
- a judgment of infringement of one or more asserted patents, and
- an injunction against FDA approval and commercial marketing of the generic product during the statutory exclusivity/remaining patent term period.
This case is presented as a patent litigation matter; however, the exact requested remedies in the complaint (e.g., specific injunction scope, bond terms, and asserted counts) are not available in the supplied inputs.
What patents were asserted and what was accused?
A complete litigation analysis requires:
- the asserted U.S. patents (numbers and expiration),
- the accused product (ANDA applicant, dosage forms, label/cartridges/tablet strengths),
- the assertion basis (direct infringement, induced, contributory, willfulness),
- and any non-infringement/invalidity defenses tied to those patents.
No asserted-patent list, claim chart references, or product identification is included in the provided information. Without those items, the infringement and invalidity analysis cannot be performed.
How did the procedural record unfold?
A high-fidelity litigation timeline normally includes:
- complaint filing and service,
- preliminary injunction briefing (if any),
- claim construction order,
- summary judgment rulings,
- trial (jury findings) or final judgment for the defendant,
- post-judgment motions,
- appeal outcomes (Federal Circuit or otherwise).
The provided input includes only the case caption and number, not the procedural milestones. As a result, a procedural summary would be incomplete if it attempted to describe events without record support.
What is the strategic patent thesis for Sanofi vs. Unimark in this case?
Even without the asserted patent list, the strategic framework for these disputes can be mapped at a “decision-useful” level:
1) Platform goal: stop launch
The core business objective in ANDA-related patent suits is a launch delay through one of three mechanisms:
- infringement finding for at least one asserted patent,
- injunction tied to a favorable claim construction,
- or settlement leading to a stipulated entry date.
Without the court’s disposition, the case’s actual strategic success cannot be scored.
2) Levers: claim scope and invalidity defenses
The most outcome-determinative levers in these cases are usually:
- claim construction that narrows or broadens the asserted claim scope, and
- invalidity arguments (anticipation, obviousness, lack of written description, enablement, indefiniteness) that attack patent validity.
No claim construction or invalidity rulings are available in the supplied inputs, so this case-specific mapping cannot be tied to court reasoning.
3) Commercial linkage: label and formulation detail
In pharmaceutical cases, the infringement analysis is tightly coupled to:
- dosage form and release profile,
- compound identity (salt form, polymorph, stereochemistry),
- and label-driven dosing regimens.
Those details are absent from the input. A formulation- or label-based non-infringement analysis would require the accused ANDA product facts and the relevant asserted claims.
What does this mean for investors or R&D planners?
A decision-grade readout requires three things:
- whether Sanofi’s case produced an injunction or final merits win,
- which patents survived (or failed) on validity/infringement, and
- whether Unimark’s entry was blocked, delayed, or achieved via design-around and settlement.
The supplied inputs do not include any of those outcomes. A business conclusion would therefore be speculative.
Key Case Artifacts Needed for a Full Merits-and-Value Assessment
A complete “litigation summary and analysis” for 1:14-cv-00876 normally includes:
- complaint and amended complaint (asserted patents, claims, infringement theory),
- Unimark’s answer and invalidity contentions,
- claim construction orders,
- dispositive motions (summary judgment / Daubert),
- trial verdict or settlement terms,
- final judgment and any appeal docket.
None of these artifacts are provided in the input. Any attempt to fill them would introduce unverified facts.
Key Takeaways
- Case identified: Sanofi v. Unimark Remedies Ltd., 1:14-cv-00876.
- But: the input contains no asserted patent numbers, accused product details, procedural events, claim construction, or final outcome, so no claim-by-claim infringement or validity analysis can be completed from record-backed facts.
- Business implication: a decision-ready assessment requires the docket’s merits outcome and the specific patents that drove the injunction/settlement narrative, which are not included here.
FAQs
1) Is this case an ANDA/Hatch-Waxman matter?
The case format and parties align with the typical structure of Hatch-Waxman disputes, but the supplied input does not include the complaint text or ANDA identifiers to confirm.
2) What patents did Sanofi assert?
The asserted patent list is not included in the provided information, so it cannot be stated accurately.
3) What did the court decide?
No disposition or judgment details are provided in the supplied input.
4) Did Unimark launch during litigation?
Launch timing and any stipulated entry date require settlement or FDA/entry documentation that is not included in the provided information.
5) What is the litigation value for Sanofi?
Litigation value depends on injunction outcomes, patent survival, and settlement terms; none of those are present in the supplied input.
References
- United States District Court docket entry for Sanofi v. Unimark Remedies Ltd., 1:14-cv-00876.
